Armuzzi A, Candelli M, Zocco M A, Andreoli A, De Lorenzo A, Nista E C, Miele L, Cremonini F, Cazzato I A, Grieco A, Gasbarrini G, Gasbarrini A
Department of Internal Medicine, Catholic University, Rome, Italy.
Aliment Pharmacol Ther. 2002 Dec;16(12):1977-96. doi: 10.1046/j.1365-2036.2002.01374.x.
Carbon-labelled breath tests were proposed as tools for the evaluation of human liver function 30 years ago, but have never become part of clinical routine. One reason for this is the complex role of the liver in metabolic regulation, making it difficult to provide essential information for the management of patients with liver disease with a single test and to satisfy the hepatology community. As a result, a battery of breath tests have been developed. Depending on the test compound administered, different metabolic pathways (microsomal, cytosolic, mitochondrial) can be examined. Most available data come from microsomal function tests, whilst information about cytosolic and mitochondrial liver function is more limited. However, breath tests have shown promise in some studies, in particular to predict the outcome of patients with chronic liver disease or to monitor hepatic function after treatment. Whilst we await new substrates that can be used to measure liver function in a more valid manner, and large prospective studies to assess the usefulness of available test compounds, the aim of this review is to describe how far we have come in this controversial and unresolved issue.
30年前,碳标记呼气试验被提议作为评估人类肝功能的工具,但从未成为临床常规检查的一部分。原因之一是肝脏在代谢调节中作用复杂,难以通过单一检测为肝病患者的管理提供关键信息并令肝病学界满意。因此,已开发出一系列呼气试验。根据所给予的测试化合物不同,可以检测不同的代谢途径(微粒体、胞质、线粒体)。大多数现有数据来自微粒体功能测试,而关于胞质和线粒体肝功能的信息则较为有限。然而,呼气试验在一些研究中已显示出前景,特别是在预测慢性肝病患者的预后或监测治疗后的肝功能方面。在我们等待能够以更有效方式用于测量肝功能的新底物以及评估现有测试化合物效用的大型前瞻性研究之际,本综述的目的是描述在这个有争议且未解决的问题上我们已经取得了多大进展。